Use of disulfiram for Neuronal Protection
US5373021A · kind A · utility
Assignee
Inventor
Key dates
| Filing date | Apr 26, 1993 |
| Grant date | Dec 13, 1994 |
| Priority date | — |
| Expiry date | Apr 26, 2013 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K45/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention discloses a rapid-diffusion injectable formulation, comprising disulfiram or a suitable salt or analog of disulfiram. Unlike slow-release injectable formulations designed to ensure that chronic alcoholics have significant quantities of disulfiram in their blood at all time, the rapid-diffusion injectable formulation disclosed herein is designed to reduce the hypoxic or ischemic damage caused by crisis events such as stroke, heart attack, cardiac arrest, or asphyxiation. A rapid-diffusion injectable formulation can contain disulfiram mixed with water, an organic compound having a plurality of hydroxyl groups (such as pharmaceutically acceptable glycols or polysaccharides; propylene glycol, dextrans, and cyclodextrins are often used for such purposes), and a buffer. When a rapid-release formulation is injected during or immediately after a hypoxic/ischemic crisis or before a patient is subjected to controlled cardiac arrest or bypass during surgery, it can suppress damage by oxygenated free radicals, it can chelate copper and iron which would otherwise promote lipid peroxidation of cell membranes, and it can generate metabolites such as tryptophol that can suppress met…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.